Sucampo Pharmaceuticals, Inc. (SCMP)

[H2R]

One of the few stocks to shine in this sell off climate. (IBX down 5% today, SCMP up 7%)

The gist of the earnings call:
Sucampo (NASDAQ:SCMP): Q2 EPS of $0.21 beats by $0.06.
Revenue of $34.88M (+44.9% Y/Y) beats by $2.98M.

And more to come:
"In Europe; Austria, Germany, and Italy issued national marketing authorizations for AMITIZA for the treatment of chronic idiopathic constipation, joining, Ireland, Luxemburg, the Netherlands, and Belgium, and we expect Spain to issue national marketing authorization by the end of this year. For Europe, Takeda continues to work on pricing and reimbursement assessments to inform their launch plans and sequencing, and continues to sell AMITIZA in Switzerland and the United Kingdom."

Analyst 'forecast' positive:

Change Over Previous Year
'15 '16 '17
54.3% 32.9% 81.7%